Predictive Oncology (POAI) 10-Q 11 Aug 22 2022 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Document Information [Line Items]
Entity Central Index Key	0001446159
Entity Registrant Name	Predictive Oncology Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-36790
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	33-1007393
Entity Address, Address Line One	2915 Commers Drive, Suite 900
Entity Address, City or Town	Eagan
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55121
City Area Code	651
Local Phone Number	389-4800
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	POAI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		78,384,339

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and Cash Equivalents	$ 28,249,452	$ 28,202,615
Accounts Receivable	336,397	354,196
Inventories	474,616	387,684
Prepaid Expense and Other Assets	763,053	513,778
Total Current Assets	29,823,518	29,458,273
Fixed Assets, net	2,300,327	2,511,571
Intangibles, net	3,790,637	3,962,118
Lease Right-of-Use Assets	505,667	814,454
Other Long-Term Assets	75,618	167,065
Goodwill	0	6,857,790
Total Assets	36,495,767	43,771,271
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts Payable	983,672	1,021,774
Accrued Expenses and other liabilities	856,654	1,262,641
Derivative Liability	32,318	129,480
Deferred Revenue	530,797	186,951
Lease Liability	421,736	639,662
Total Current Liabilities	2,825,177	3,240,508
Lease Liability – Net of current portion	113,462	239,664
Other long-term liabilities	21,731	25,415
Total Liabilities	2,960,370	3,505,587
Stockholders’ Equity:
Common Stock, $.01 par value, 200,000,000 shares authorized, 78,155,127 and 65,614,597 outstanding	781,551	656,146
Additional paid-in capital	174,555,375	167,649,028
Accumulated Deficit	(141,802,321)	(128,040,282)
Total Stockholders’ Equity	33,535,397	40,265,684
Total Liabilities and Stockholders’ Equity	36,495,767	43,771,271
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Preferred Stock, 20,000,000 authorized inclusive of designated below Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding	$ 792	$ 792

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares outstanding (in shares)	78,155,127	65,614,597
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized (in shares)	2,300,000	2,300,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares outstanding (in shares)	79,246	79,246

Condensed Consolidated Statemen

Condensed Consolidated Statements of Net Loss (Unaudited) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue		$ 371,591	$ 350,207	$ 686,159	$ 630,524
Cost of goods sold		134,075	142,877	243,518	240,635
Gross profit		237,516	207,330	442,641	389,889
General and administrative expense		2,351,696	2,077,973	4,775,347	5,348,750
Operations expense		909,113	567,796	1,800,184	1,142,608
Sales and marketing expense		271,022	159,788	575,489	274,429
Loss on impairment of goodwill		7,231,093	0	7,231,093	0
Total operating loss		(10,525,408)	(2,598,227)	(13,939,472)	(6,375,898)
Other income		41,047	57,033	83,477	85,292
Other expense		(2,217)	(1,829)	(3,206)	(236,801)
Gain (loss) on derivative instruments		95,254	(30,909)	97,162	64,762
Net loss		(10,391,324)	(2,573,932)	(13,762,039)	(6,462,645)
Net loss attributable to common shareholders per common shares-basic and diluted		$ (10,391,324)	$ (2,573,932)	$ (13,762,039)	$ (6,462,645)
Loss per common share basic (in dollars per share)		$ (0.15)	$ (0.05)	$ (0.20)	$ (0.15)
Loss per common share diluted (in dollars per share)		$ (0.15)	$ (0.05)	$ (0.20)	$ (0.15)
Weighted average shared used in computation - basic (in shares)	[1]	68,896,506	51,581,762	67,374,250	44,089,157
Weighted average shared used in computation - diluted (in shares)		68,896,506	51,581,762	67,374,250	44,089,157
[1]The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Six Months ended June 30, 2022 2021 Options 1,035,245 1,013,780 Restricted Stock Units 366,666 325,000 Warrants 36,398,526 31,747,118 Preferred stock: series B 79,246 79,246

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Registered Direct Offerings [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Private Placement [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member] June 16, 2021 Registered Direct Offering [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member] Registered Direct Offerings [Member]	Common Stock [Member] Private Placement [Member]	Common Stock [Member] June 16, 2021 Registered Direct Offering [Member]	Common Stock [Member]	Additional Paid-in Capital [Member] Registered Direct Offerings [Member]	Additional Paid-in Capital [Member] Private Placement [Member]	Additional Paid-in Capital [Member] June 16, 2021 Registered Direct Offering [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member] Registered Direct Offerings [Member]	Retained Earnings [Member] Private Placement [Member]	Retained Earnings [Member] June 16, 2021 Registered Direct Offering [Member]	Retained Earnings [Member]	Registered Direct Offerings [Member]	Private Placement [Member]	June 16, 2021 Registered Direct Offering [Member]	Total
Balance (in shares) at Dec. 31, 2020				79,246				19,804,787
Balance at Dec. 31, 2020				$ 792				$ 198,048				$ 110,826,949				$ (108,383,108)				$ 2,642,681
Shares issued to consultant & other (in shares)								2,665
Shares issued to consultant & other								$ 27				(4,075)								(4,048)
Vesting expense												565,082								565,082
Net loss																(3,888,713)				(3,888,713)
Issuance of shares and warrants (in shares)					13,488,098	9,043,766
Issuance of shares and warrants					$ 134,881	$ 90,438			$ 14,877,611	$ 15,974,301							$ 15,012,492	$ 16,064,739
Shares issued pursuant to agreement with former CEO related to accrued interest (in shares)								100,401
Shares issued pursuant to agreement with former CEO related to accrued interest								$ 1,004				142,569								143,573
Exercise of warrants (in shares)								5,247,059
Exercise of warrants								$ 52,471				4,442,799								4,495,270
Shares issued pursuant to convertible debt (in shares)								1,107,544
Shares issued pursuant to convertible debt								$ 11,075				502,936								514,011
Balance (in shares) at Mar. 31, 2021				79,246				48,794,320
Balance at Mar. 31, 2021				$ 792				$ 487,944				147,328,172				(112,271,821)				35,545,087
Balance (in shares) at Dec. 31, 2020				79,246				19,804,787
Balance at Dec. 31, 2020				$ 792				$ 198,048				110,826,949				(108,383,108)				2,642,681
Net loss																				(6,462,645)
Balance (in shares) at Jun. 30, 2021				79,246				65,335,159
Balance at Jun. 30, 2021				$ 792				$ 653,352				167,279,695				(114,845,753)				53,088,086
Balance (in shares) at Mar. 31, 2021				79,246				48,794,320
Balance at Mar. 31, 2021				$ 792				$ 487,944				147,328,172				(112,271,821)				35,545,087
Shares issued pursuant to equity line (in shares)								572,504
Shares issued pursuant to equity line								$ 5,725				582,865								588,590
Shares issued to consultant & other (in shares)								47,424
Shares issued to consultant & other								$ 474				48,238								48,802
Vesting expense												33,243								33,243
Net loss																(2,573,932)				(2,573,932)
Issuance of shares and warrants (in shares)							15,520,911
Issuance of shares and warrants							$ 155,209				$ 19,291,087								$ 19,446,296
Shares issued pursuant to transition agreement with former CEO (in shares)								400,000
Shares issued pursuant to transition agreement with former CEO								$ 4,000				(4,000)								0
Balance (in shares) at Jun. 30, 2021				79,246				65,335,159
Balance at Jun. 30, 2021				$ 792				$ 653,352				167,279,695				(114,845,753)				53,088,086
Balance (in shares) at Dec. 31, 2021				79,246				65,614,597
Balance at Dec. 31, 2021				$ 792				$ 656,146				167,649,028				(128,040,282)				40,265,684
Shares issued pursuant to equity line (in shares)								120,000
Shares issued pursuant to equity line								$ 1,200				85,685								86,885
Shares issued to consultant & other (in shares)								171,868
Shares issued to consultant & other								$ 1,719				160,403								162,122
Vesting expense												36,518								36,518
Net loss																(3,370,715)				(3,370,715)
Balance (in shares) at Mar. 31, 2022				79,246				65,906,465
Balance at Mar. 31, 2022				$ 792				$ 659,065				167,931,634				(131,410,997)				37,180,494
Balance (in shares) at Dec. 31, 2021				79,246				65,614,597
Balance at Dec. 31, 2021				$ 792				$ 656,146				167,649,028				(128,040,282)				40,265,684
Net loss																				(13,762,039)
Balance (in shares) at Jun. 30, 2022				79,246				78,155,127
Balance at Jun. 30, 2022				$ 792				$ 781,551				174,555,375				(141,802,321)				33,535,397
Balance (in shares) at Mar. 31, 2022				79,246				65,906,465
Balance at Mar. 31, 2022				$ 792				$ 659,065				167,931,634				(131,410,997)				37,180,494
Shares issued pursuant to equity line (in shares)								195,000
Shares issued pursuant to equity line								$ 1,950				147,174								149,124
Shares issued to consultant & other (in shares)								53,662
Shares issued to consultant & other								$ 536				50,134								50,670
Vesting expense												39,383								39,383
Net loss																(10,391,324)				(10,391,324)
Issuance of shares and warrants (in shares)								12,000,000
Issuance of shares and warrants								$ 120,000				6,387,050								6,507,050
Balance (in shares) at Jun. 30, 2022				79,246				78,155,127
Balance at Jun. 30, 2022				$ 792				$ 781,551				$ 174,555,375				$ (141,802,321)				$ 33,535,397

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flow from operating activities:
Net loss	$ (13,762,039)	$ (6,462,645)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	649,441	649,126
Vesting expense	75,901	598,325
Common stock issued for consulting and other	212,792	0
Amortization of debt discount	0	244,830
Gain on valuation of equity-linked instruments and derivative liability	(97,162)	(64,762)
Equity instruments issued management, consultant, and other		52,471
Loss on impairment of goodwill	7,231,093	0
Loss on fixed asset disposal	1,700	0
Changes in assets and liabilities:
Accounts receivable	17,799	60,358
Inventories	(86,931)	(28,291)
Prepaid expense and other assets	(157,827)	39,852
Accounts payable	(38,104)	(430,110)
Accrued expenses and other liabilities	(441,328)	(198,890)
Deferred revenue	(29,457)	101,317
Other long-term liabilities	(3,684)	(88,559)
Net cash used in operating activities:	(6,427,806)	(5,526,978)
Cash flow from investing activities:
Purchase of fixed assets	(233,572)	(610,906)
Acquisition of intangibles	(34,844)	(22,870)
Net cash used in investing activities	(268,416)	(633,776)
Cash flow from financing activities:
Proceeds from issuance of common stock and warrants, net	6,507,050	50,515,810
Proceeds from exercise of warrants into common stock	0	4,495,270
Repayment of debt	0	(4,162,744)
Payment penalties	0	(1,073,470)
Proceeds from issuance of common stock pursuant to equity line	236,009	588,590
Net cash provided by financing activities	6,743,059	50,363,456
Net increase in cash and cash equivalents	46,837	44,202,702
Cash and cash equivalents at beginning of period	28,202,615	678,332
Cash and cash equivalents at end of period	28,249,452	44,881,034
Non-cash transactions:
Shares issued to CEO per agreement related to accrued interest	0	143,573
Shares issued pursuant to convertible debt	0	514,011
Cash paid during period for:
Interest paid	$ 1,439	$ 694,435

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Operations and Continuance of Operations Predictive Oncology Inc.®, (the “Company” or “Predictive” or “we”) filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name to Predictive Oncology Inc. on June 10, 2019, June 13, 2019. The Company operates in four The Company had cash and cash equivalents of $28,249,452 as of June 30, 2022. June 30, 2022, twelve may Coronavirus Outbreak The current COVID- 19 19 19 may 19 may 19 10 March 31, 2022. Interim Financial Statements The Company has prepared the condensed consolidated financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim condensed consolidated financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations, and its cash flows for the interim periods. These interim condensed consolidated financial statements reflect all intercompany eliminations. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto contained in the Annual Report on Form 10 March 31, 2022. may not Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates. Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not June 30, 2022 December 31, 2021. Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Derivatives Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first Fixed Assets Fixed assets are stated at cost less accumulated depreciation and amortization. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred. Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 Note 4 Intangible Assets and Goodwill Leases ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within the Skyline segment. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing The Tumor Drug Response test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression of a particular gene related to a patient’s tumor specimen. The Company’s clinical diagnostic testing is comprised of the Company’s Tumor Drug Response Testing (formerly ChemoFx) and genomic/proteomic tests (formerly BioSpeciFx) tests. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics’ payment terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience. The Company uses a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect less consideration than it originally estimated for a contract with a patient, it will account for the change as a decrease to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $336,397 and $354,196 as of June 30, 2022 December 31, 2021, The Company’s deferred revenues related primarily to maintenance plans and payments received in advance of providing services under certain contracts. Deferred revenue was $530,797 and $186,951 as of June 30, 2022 December 31, 2021, June 30, 2022. one Practical Expedients The Company has elected the practical expedient not Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the six months ended June 30, 2022 2021 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 86.5% – 92.2% 84.8 – 89.6% Risk-free interest rate 1.83% – 3.43% 0.93% – 1.45% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 92.2% 84.8% Risk-free interest rate 2.96% – 2.97% 0.42% – 0.69% Expected life (years) 5 – 5.5 5 – 5.5 Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $101,612 and $143,322 for the six June 30, 2022 2021, Other Expense Other expense consisted primarily of interest expense, payment premium, amortization of original issue discounts, and loss on debt extinguishment associated with the Company’s notes payable. Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering unless such costs are deemed to be insignificant in which case they are expensed as incurred. Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no income tax provision in the accompanying condensed consolidated statements of net loss due to the cumulative operating losses that indicate a 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2018 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one zero Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 2 - Inventories

Note 2 - Inventories	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 2 INVENTORIES Inventory balances are as follows: As of June 30, 2022 As of December 31, 2021 Finished goods $ 282,268 $ 193,287 Raw materials 186,043 183,410 Work-In-Process 6,305 10,987 Total $ 474,616 $ 387,684

Note 3 - Fixed Assets

Note 3 - Fixed Assets	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 3 FIXED ASSETS The Company’s fixed assets consist of the following: As of June 30, 2022 As of December 31, 2021 Computers, software, and office equipment $ 540,116 $ 517,488 Leasehold improvements 427,296 428,596 Laboratory equipment 3,665,970 3,456,091 Manufacturing tooling 121,120 121,120 Demo equipment 31,555 56,614 Total 4,786,057 4,579,909 Less: Accumulated depreciation and amortization (2,485,730 ) (2,068,338 ) Total Fixed Assets, Net $ 2,300,327 $ 2,511,571 Depreciation expense was $222,473 and $244,062 for the three June 30, 2022 2021, six June 30, 2022 2021,

Note 4 - Intangible Assets and

Note 4 - Intangible Assets and Goodwill	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 4 INTANGIBLE ASSETS AND GOODWILL The components of intangible assets were as follows: As of June 30, 2022 As of December 31, 2021 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Impairment Net Carrying Amount Patents & Trademarks $ 488,724 $ (241,583 ) $ 247,141 $ 453,314 $ (230,572 ) $ - $ 222,742 Developed Technology 3,500,000 (211,458 ) 3,288,542 6,382,000 (432,733 ) (2,485,725 ) 3,463,542 Customer Relationships 200,000 (12,083 ) 187,917 645,000 (410,000 ) (37,083 ) 197,917 Tradename 80,000 (12,963 ) 67,037 478,000 (29,343 ) (370,740 ) 77,917 Total $ 4,268,724 $ (478,087 ) $ 3,790,637 $ 7,958,314 $ (1,102,648 ) $ (2,893,548 ) $ 3,962,118 The impairment loss recognized during the year ended December 31, 2021 June 30, 2022 360 10 35 20. three June 30, 2022 2021, six June 30, 2022 2021, The following table outlines the estimated future amortization expense related to intangible assets held as of June 30, 2020: Year ending December 31, Expense 2022 $ 207,068 2023 414,139 2024 414,139 2025 412,056 2026 394,139 Thereafter 1,949,096 Total $ 3,790,637 The Company concluded there was no impairment of its finite-lived assets as of June 30, 2022. 360. Goodwill Goodwill for our zPREDICTA operating segment was zero as of June 30, 2022 December 31, 2021. December 31, 2021 June 30, 2022. second 2022 During the three June 30, 2022, 606 three June 30, 2022 The Company evaluated the materiality of these errors both qualitatively and quantitatively in accordance with Staff Accounting Bulletin (“SAB”) No. 99, No. 108, not December 31, 2021 June 30, 2022 March 31, 2022. The Company had previously disclosed the zPREDICTA acquisition date fair values of assets acquired and liabilities assumed, and the consideration transferred, the following table reflects the adjustment discussed above: Cash consideration $ 10,015,941 Assets acquired: Cash 425,727 Accounts receivable 76,549 Prepaid expenses 25,733 Intangible assets 3,780,000 Liabilities assumed: Accrued expenses (408,825 ) Deferred tax liability (661,658 ) Deferred revenue (452,678 ) Goodwill $ 7,231,093 Pro Forma The following pro forma information presents the combined results of operations of the Company and zPREDICTA as if the acquisition of zPREDICTA had been completed on January 1, 2020, 606 2021 2020 Unaudited Unaudited Revenue $ 2,056,484 $ 1,815,560 Net loss attributable to common shareholders $ (19,251,734 ) $ (26,946,564 ) During the second 2022, June 30, 2022, June 30, 2022. zPREDICTA reporting unit The quantitative review as of June 30, 2022 June 30, 2022, Goodwill balance at December 31, 2021 $ 6,857,790 Adjustment to fair value 373,303 Impairment (7,231,093 ) Goodwill balance at June 30, 2022 $ - When evaluating the fair value of zPREDICTA reporting unit, the Company used a discounted cash flow model and market comparisons. Key assumptions used to determine the estimated fair value included: (a) expected cash flow for the 10-year period following the testing date (including net revenues, costs of revenues, and operating expenses as well as estimated working capital needs and capital expenditures) and (b) an estimated terminal value using a terminal year growth rate of 4.0% determined based on the growth prospects of the reporting unit. The Company further used a probability weighting of various forecasts to address forecast risk. The Company used an estimated discount rate of 65% based on management’s best estimate and considering the Company’s current market capitalization. The majority of the inputs used in the discounted cash flow model are unobservable and thus are considered to be Level 3 1 not Helomics reporting unit The goodwill, for our Helomics operating segment, was zero at June 30, 2022 December 31, 2021,

Note 5 - Stockholders' Equity,

Note 5 - Stockholders' Equity, Stock Options and Warrants	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 5 STOCKHOLDERS EQUITY, STOCK OPTIONS AND WARRANTS May 2022 On May 16, 2022, six five one In addition, in a concurrent registered direct offering (the “Second Offering”), on May 16, 2022, 2020 2021 not six five one In each case, the Company paid to the placement agent an aggregate fee equal to 7.5% of the aggregate gross proceeds received by the Company in the offering and a management fee equal to 1% of the aggregate gross proceeds received by the Company in the offering and provided the placement agent expense allowance of $65,000 for non-accountable and other out-of-pocket expenses. In addition, the Company granted to the placement agent or its assigns warrants to purchase 7.5% of the shares sold to investors in the offering at an exercise price equal to 125% of the price of the shares in the transaction, or $0.75 per share, with a term of five six Equity Line On October 24, 2019, three three may June 30, 2022, May 2022 not one May 18, 2022. six June 30, 2022, Equity Incentive Plan The Company has an equity incentive plan, which allows the Company to issue incentive and non-qualified stock options to employees, directors, and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 1.99 Issued 147,230 1.06 29,640,801 1.44 Forfeited (92,593 ) 8.64 - - Expired - - (25,233 ) 10.00 Exercised (5,313 ) 0.74 (5,269,059 ) 0.86 Outstanding at December 31, 2021 1,062,871 $ 4.83 31,699,885 $ 1.66 Issued 14,075 0.51 21,062,714 0.70 Forfeited - - (38,640 ) - Expired (41,701 ) 13.41 (16,325,433 ) 26.91 Outstanding at June 30, 2022 1,035,245 $ 4.49 36,398,526 $ 0.74 Stock-based compensation expense recognized for three June 30, 2022 2021 six June 30, 2022 2021 June 30, 2022,

Note 6 - Derivatives

Note 6 - Derivatives	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Derivative Instruments and Hedging Activities Disclosure [Text Block]	NOTE 6 DERIVATIVES Certain warrants issued to placement agents were determined to be a derivative liability due to certain features of the warrants which could, in certain circumstances, result in the holder receiving the Black Scholes value of the outstanding warrants in the same type of consideration as the common stockholders. As a result, in those circumstances, the amount of consideration would differ from that provided to holders of common stock, therefore, the warrants were classified as a liability. The fair value of the agent warrants issued in connection with a March 2020 December 31, 2021. six June 30, 2022 six June 30, 2021. June 30, 2022, The fair value of the agent warrants issued in connection with the May 2020 June 30, 2022 December 31, 2021, six June 30, 2022 six June 30, 2021. The placement agent warrants issued in connection with the June 2020 June 30, 2022 December 31, 2021, six June 30, 2022 six June 30, 2021. The table below discloses changes in value of the Company’s embedded derivative liabilities discussed above. Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (95,671 ) Derivative liability balance at March 31, 2021 $ 198,711 Gain recognized to revalue derivative instrument at fair value 30,909 Derivative liability balance at June 30, 2021 $ 229,620 Derivative liability balance at December 31, 2021 $ 129,480 Gain recognized to revalue derivative instrument at fair value (1,908 ) Derivative liability balance at March 31, 2022 $ 127,572 Gain recognized to revalue derivative instrument at fair value (95,254 ) Derivative liability balance at June 30, 2022 $ 32,318

Note 7 - Loss Per Share

Note 7 - Loss Per Share	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (10,391,324 ) $ (2,573,932 ) $ (13,762,039 ) $ (6,462,645 ) Denominator: Weighted average common shares outstanding-basic (1) 68,896,506 51,581,762 67,374,250 44,089,157 Effect of diluted stock options, warrants, and preferred stock (2) - - - - Weighted average common shares outstanding - diluted 68,896,506 51,581,762 67,374,250 44,089,157 Loss per common share-basic $ (0.15 ) $ (0.05 ) $ (0.20 ) $ (0.15 ) Loss per common share- diluted $ (0.15 ) $ (0.05 ) $ (0.20 ) $ (0.15 ) ( 1 The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Six Months ended June 30, 2022 2021 Options 1,035,245 1,013,780 Restricted Stock Units 366,666 325,000 Warrants 36,398,526 31,747,118 Preferred stock: series B 79,246 79,246

Note 8 - Segments

Note 8 - Segments	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	NOTE 8 SEGMENTS The Company has determined its operating segments in accordance with ASC 280 Segment Reporting The Company has four reportable segments: Helomics, zPREDICTA, Soluble and Skyline. See discussion of revenue recognition in Note 1 three six June 30, 2022 2021 Revenue Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Helomics $ 84 $ 7,161 $ 3,722 $ 9,151 Soluble 22,225 34,910 35,141 48,985 zPREDICTA 71,941 - 90,283 Skyline 276,854 306,136 556,124 570,388 Corporate 487 2,000 889 2,000 Total $ 371,591 $ 350,207 $ 686,159 $ 630,524 Segment Gain (Loss) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Helomics $ (946,341 ) $ (1,057,177 ) $ (1,986,069 ) $ (2,284,853 ) Soluble (396,100 ) (238,938 ) (798,928 ) (488,467 ) zPREDICTA (7,554,404 ) - (7,829,190 ) - Skyline (101,434 ) (133,082 ) (150,035 ) (275,640 ) Corporate (1,393,045 ) (1,144,735 ) (2,997,817 ) (3,413,685 ) Total $ (10,391,324 ) $ (2,573,932 ) $ (13,762,039 ) $ (6,462,645 ) Assets As of June 30, As of December 31, 2022 2021 Helomics $ 1,275,404 $ 1,802,792 Soluble 1,565,394 1,742,445 zPREDICTA 3,782,143 10,782,568 Skyline 14,750,103 906,977 Corporate 15,122,723 (28,536,489 ) Total $ 36,495,767 $ 43,771,271

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 RELATED PARTY TRANSACTIONS The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may no six June 30, 2022.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Predictive Oncology Inc.®, (the “Company” or “Predictive” or “we”) filed with the Secretary of State of Delaware a Certificate of Amendment to its Certificate of Incorporation to change the corporate name to Predictive Oncology Inc. on June 10, 2019, June 13, 2019. The Company operates in four The Company had cash and cash equivalents of $28,249,452 as of June 30, 2022. June 30, 2022, twelve may
Effect of Covid-19 Pandemic [Policy Text Block]	Coronavirus Outbreak The current COVID- 19 19 19 may 19 may 19 10 March 31, 2022.
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and during the reporting period. Actual results could materially differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all highly liquid instruments with maturities when purchased of three
Receivable [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation allowance based on management’s assessment of the status of individual accounts. Amounts recorded in accounts receivable on the condensed consolidated balance sheet include amounts billed and currently due from customers. The amounts due are stated at their net estimated realizable value. An allowance for doubtful accounts is maintained to provide for the estimated amount of receivables that will not 30 30 not June 30, 2022 December 31, 2021.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements As outlined in Accounting Standards Codification (“ASC”) 820, Fair Value Measurement 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities, which consist of cash and cash equivalents, was determined based on Level 1 3 Note 7 Derivatives
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first first
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost less accumulated depreciation and amortization. Depreciation of fixed assets is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3 ( 1 Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term. Upon retirement or sale of fixed assets, the cost and related accumulated depreciation or amortization are removed from the condensed consolidated balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations expense as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Long-lived Assets Finite-lived intangible assets consist of patents and trademarks, licensing fees, developed technology, and customer relationships, and are amortized over their estimated useful life. Accumulated amortization is included in intangibles, net in the accompanying condensed consolidated balance sheets. The Company reviews finite-lived identifiable intangible assets for impairment in accordance with ASC 360, Property, Plant and Equipment may not may not not
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill In accordance with ASC 350, Intangibles Goodwill and Other not December 31, may not To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first not may first 2017 04, Simplifying the Test for Goodwill Impairment 3 1 Note 4 Intangible Assets and Goodwill
Lessee, Leases [Policy Text Block]	Leases ROU assets represent our right to use an underlying asset for the duration of the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Recognition on the commencement date is based on the present value of lease payments over the lease term using an incremental borrowing rate. Leases with a term of 12 not The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component for all asset classes. Leases are accounted for at a portfolio level when similar in nature with identical or nearly identical provisions and similar effective dates and lease terms.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. Sales taxes are excluded from revenue and expenses. Revenue from Product Sales The Company has medical device revenue consisting primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. This revenue stream is reported within the Skyline segment. The Company sells its medical device products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping, and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, and Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and acceptance of its Terms and Conditions to be a customer’s contract in all cases. Product sales for medical devices consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: ( 1 2 3 4 may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction for medical devices related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. This revenue stream is reported under the Skyline reportable segment. Revenue from Clinical Testing The Tumor Drug Response test determines how a patient’s tumor specimen reacts to a panel of various chemotherapy drugs, while the Genomic Profiling test evaluates the expression of a particular gene related to a patient’s tumor specimen. The Company’s clinical diagnostic testing is comprised of the Company’s Tumor Drug Response Testing (formerly ChemoFx) and genomic/proteomic tests (formerly BioSpeciFx) tests. Revenues are recognized when control of the promised goods or services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The estimated uncollectible amounts are generally considered implicit price concessions that are a reduction in revenue. Helomics’ payment terms vary by the agreements reached with insurance carriers and Medicare. The Company’s performance obligations are satisfied at one For service revenues, the Company estimates the transaction price which is the amount of consideration it expects to be entitled to receive in exchange for providing services based on its historical collection experience. The Company uses a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect less consideration than it originally estimated for a contract with a patient, it will account for the change as a decrease to the estimate of the transaction price, provided that such downward adjustment does not The Company recognizes revenue from these patients when contracts as defined in ASC 606, Revenue from Contracts with Customers 30 CRO Revenue Contract revenues are generally derived from studies conducted with biopharmaceutical and pharmaceutical companies. The specific methodology for revenue recognition is determined on a case-by-case basis according to the facts and circumstances applicable to a given contract. The Company typically uses an input method that recognizes revenue based on the Company’s efforts to satisfy the performance obligation relative to the total expected inputs to the satisfaction of that performance obligation. For contracts with multiple performance obligations, the Company allocates the contract’s transaction price to each performance obligation on the basis of the standalone-selling price of each distinct good or service in the contract. Advance payments received in excess of revenues recognized are classified as deferred revenue until such time as the revenue recognition criteria have been met. Payment terms are net 30 Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. Accounts receivable totaled $336,397 and $354,196 as of June 30, 2022 December 31, 2021, The Company’s deferred revenues related primarily to maintenance plans and payments received in advance of providing services under certain contracts. Deferred revenue was $530,797 and $186,951 as of June 30, 2022 December 31, 2021, June 30, 2022. one Practical Expedients The Company has elected the practical expedient not
Valuation and Accounting for Stock Options and Warrants, Policy [Policy Text Block]	Valuation and accounting for stock options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility, and estimated term. The fair value of each option and warrant grant is estimated on the grant date using the Black-Scholes option valuation model with the following assumptions: For the six months ended June 30, 2022 2021 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 86.5% – 92.2% 84.8 – 89.6% Risk-free interest rate 1.83% – 3.43% 0.93% – 1.45% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 92.2% 84.8% Risk-free interest rate 2.96% – 2.97% 0.42% – 0.69% Expected life (years) 5 – 5.5 5 – 5.5
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were $101,612 and $143,322 for the six June 30, 2022 2021,
Other Expense Policy [Policy Text Block]	Other Expense Other expense consisted primarily of interest expense, payment premium, amortization of original issue discounts, and loss on debt extinguishment associated with the Company’s notes payable.
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes 740” 740, There is no income tax provision in the accompanying condensed consolidated statements of net loss due to the cumulative operating losses that indicate a 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not Under Internal Revenue Code Section 382, may not not 382 may Tax years subsequent to 2018
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one zero
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device and biopharmaceutical industries, including, but not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (the “FASB”). Recently issued ASUs not not no In June 2016, 2016 13, not 12b 2 1934, January 1, 2023.

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers, software, and office equipment 3 - 10 Leasehold improvements (1) 2 - 5 Manufacturing tooling 3 - 7 Laboratory equipment 4 - 10 Demo equipment 3
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	For the six months ended June 30, 2022 2021 Stock Options Expected dividend yield 0.0% 0.0% Expected stock price volatility 86.5% – 92.2% 84.8 – 89.6% Risk-free interest rate 1.83% – 3.43% 0.93% – 1.45% Expected life (years) 10 10 Warrants Expected dividend yield 0.0% 0.0% Expected stock price volatility 92.2% 84.8% Risk-free interest rate 2.96% – 2.97% 0.42% – 0.69% Expected life (years) 5 – 5.5 5 – 5.5

Note 2 - Inventories (Tables)

Note 2 - Inventories (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Inventory, Current [Table Text Block]	As of June 30, 2022 As of December 31, 2021 Finished goods $ 282,268 $ 193,287 Raw materials 186,043 183,410 Work-In-Process 6,305 10,987 Total $ 474,616 $ 387,684

Note 3 - Fixed Assets (Tables)

Note 3 - Fixed Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Property, Plant and Equipment [Table Text Block]	As of June 30, 2022 As of December 31, 2021 Computers, software, and office equipment $ 540,116 $ 517,488 Leasehold improvements 427,296 428,596 Laboratory equipment 3,665,970 3,456,091 Manufacturing tooling 121,120 121,120 Demo equipment 31,555 56,614 Total 4,786,057 4,579,909 Less: Accumulated depreciation and amortization (2,485,730 ) (2,068,338 ) Total Fixed Assets, Net $ 2,300,327 $ 2,511,571

Note 4 - Intangible Assets an_2

Note 4 - Intangible Assets and Goodwill (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of June 30, 2022 As of December 31, 2021 Gross Carrying Costs Accumulated Amortization Net Carrying Amount Gross Carrying Costs Accumulated Amortization Impairment Net Carrying Amount Patents & Trademarks $ 488,724 $ (241,583 ) $ 247,141 $ 453,314 $ (230,572 ) $ - $ 222,742 Developed Technology 3,500,000 (211,458 ) 3,288,542 6,382,000 (432,733 ) (2,485,725 ) 3,463,542 Customer Relationships 200,000 (12,083 ) 187,917 645,000 (410,000 ) (37,083 ) 197,917 Tradename 80,000 (12,963 ) 67,037 478,000 (29,343 ) (370,740 ) 77,917 Total $ 4,268,724 $ (478,087 ) $ 3,790,637 $ 7,958,314 $ (1,102,648 ) $ (2,893,548 ) $ 3,962,118
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year ending December 31, Expense 2022 $ 207,068 2023 414,139 2024 414,139 2025 412,056 2026 394,139 Thereafter 1,949,096 Total $ 3,790,637
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Cash consideration $ 10,015,941 Assets acquired: Cash 425,727 Accounts receivable 76,549 Prepaid expenses 25,733 Intangible assets 3,780,000 Liabilities assumed: Accrued expenses (408,825 ) Deferred tax liability (661,658 ) Deferred revenue (452,678 ) Goodwill $ 7,231,093
Business Acquisition, Pro Forma Information [Table Text Block]	2021 2020 Unaudited Unaudited Revenue $ 2,056,484 $ 1,815,560 Net loss attributable to common shareholders $ (19,251,734 ) $ (26,946,564 )
Schedule of Goodwill [Table Text Block]	Goodwill balance at December 31, 2021 $ 6,857,790 Adjustment to fair value 373,303 Impairment (7,231,093 ) Goodwill balance at June 30, 2022 $ -

Note 5 - Stockholders' Equity_2

Note 5 - Stockholders' Equity, Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Share-Based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Shares Average Exercise Price Number of Shares Average Exercise Price Outstanding at December 31, 2020 1,013,547 $ 5.41 7,353,376 $ 1.99 Issued 147,230 1.06 29,640,801 1.44 Forfeited (92,593 ) 8.64 - - Expired - - (25,233 ) 10.00 Exercised (5,313 ) 0.74 (5,269,059 ) 0.86 Outstanding at December 31, 2021 1,062,871 $ 4.83 31,699,885 $ 1.66 Issued 14,075 0.51 21,062,714 0.70 Forfeited - - (38,640 ) - Expired (41,701 ) 13.41 (16,325,433 ) 26.91 Outstanding at June 30, 2022 1,035,245 $ 4.49 36,398,526 $ 0.74

Note 6 - Derivatives (Tables)

Note 6 - Derivatives (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative liability balance at December 31, 2020 $ 294,382 Gain recognized to revalue derivative instrument at fair value (95,671 ) Derivative liability balance at March 31, 2021 $ 198,711 Gain recognized to revalue derivative instrument at fair value 30,909 Derivative liability balance at June 30, 2021 $ 229,620 Derivative liability balance at December 31, 2021 $ 129,480 Gain recognized to revalue derivative instrument at fair value (1,908 ) Derivative liability balance at March 31, 2022 $ 127,572 Gain recognized to revalue derivative instrument at fair value (95,254 ) Derivative liability balance at June 30, 2022 $ 32,318

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss attributable to common shareholders per common share: basic and diluted calculation $ (10,391,324 ) $ (2,573,932 ) $ (13,762,039 ) $ (6,462,645 ) Denominator: Weighted average common shares outstanding-basic (1) 68,896,506 51,581,762 67,374,250 44,089,157 Effect of diluted stock options, warrants, and preferred stock (2) - - - - Weighted average common shares outstanding - diluted 68,896,506 51,581,762 67,374,250 44,089,157 Loss per common share-basic $ (0.15 ) $ (0.05 ) $ (0.20 ) $ (0.15 ) Loss per common share- diluted $ (0.15 ) $ (0.05 ) $ (0.20 ) $ (0.15 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Six Months ended June 30, 2022 2021 Options 1,035,245 1,013,780 Restricted Stock Units 366,666 325,000 Warrants 36,398,526 31,747,118 Preferred stock: series B 79,246 79,246

Note 8 - Segments (Tables)

Note 8 - Segments (Tables)	6 Months Ended
	Jun. 30, 2022
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Helomics $ 84 $ 7,161 $ 3,722 $ 9,151 Soluble 22,225 34,910 35,141 48,985 zPREDICTA 71,941 - 90,283 Skyline 276,854 306,136 556,124 570,388 Corporate 487 2,000 889 2,000 Total $ 371,591 $ 350,207 $ 686,159 $ 630,524 Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Helomics $ (946,341 ) $ (1,057,177 ) $ (1,986,069 ) $ (2,284,853 ) Soluble (396,100 ) (238,938 ) (798,928 ) (488,467 ) zPREDICTA (7,554,404 ) - (7,829,190 ) - Skyline (101,434 ) (133,082 ) (150,035 ) (275,640 ) Corporate (1,393,045 ) (1,144,735 ) (2,997,817 ) (3,413,685 ) Total $ (10,391,324 ) $ (2,573,932 ) $ (13,762,039 ) $ (6,462,645 ) As of June 30, As of December 31, 2022 2021 Helomics $ 1,275,404 $ 1,802,792 Soluble 1,565,394 1,742,445 zPREDICTA 3,782,143 10,782,568 Skyline 14,750,103 906,977 Corporate 15,122,723 (28,536,489 ) Total $ 36,495,767 $ 43,771,271

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash and Cash Equivalents, at Carrying Value, Total	$ 28,249,452		$ 28,202,615
Long-term Debt, Total	0
Accounts Receivable, Allowance for Credit Loss, Current	0		0
Accounts Receivable, after Allowance for Credit Loss, Total	336,397		354,196
Contract with Customer, Liability, Total	530,797		$ 186,951
Research and Development Expense, Total	101,612	$ 143,322
Income Tax Expense (Benefit), Total	0
Unrecognized Tax Benefits, Ending Balance	0
zPREDICTA [Member]
Contract with Customer, Liability, Total	$ 476,677

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	6 Months Ended
	Jun. 30, 2022
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	2 years	[1]
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	4 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	10 years
Maximum [Member] | Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years	[1]
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Property, plant, and equipment, useful life (Year)	10 years
[1]Leasehold improvements are amortized over the shorter of the useful life or the remaining lease term.

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Expected dividend yield	0%	0%
Expected life (years) (Year)	10 years	10 years
Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.922	0.848
Minimum [Member]
Expected stock price volatility	86.50%	84.80%
Risk-free interest rate	1.83%	0.93%
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0296	0.0042
Minimum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5	5
Maximum [Member]
Expected stock price volatility	92.20%	89.60%
Risk-free interest rate	3.43%	1.45%
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0297	0.0069
Maximum [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input	5.5	5.5

Note 2 - Inventories - Schedule

Note 2 - Inventories - Schedule of Inventory (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Finished goods	$ 282,268	$ 193,287
Raw materials	186,043	183,410
Work-In-Process	6,305	10,987
Total	$ 474,616	$ 387,684

Note 3 - Fixed Assets (Details

Note 3 - Fixed Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Depreciation, Total	$ 222,473	$ 244,062	$ 442,551	$ 482,993

Note 3 - Fixed Assets - Schedul

Note 3 - Fixed Assets - Schedule of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Property, Plant, and Equipment Gross	$ 4,786,057	$ 4,579,909
Less: Accumulated depreciation and amortization	(2,485,730)	(2,068,338)
Total Fixed Assets, Net	2,300,327	2,511,571
Office Equipment [Member]
Property, Plant, and Equipment Gross	540,116	517,488
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	427,296	428,596
Laboratory Equipment [Member]
Property, Plant, and Equipment Gross	3,665,970	3,456,091
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	121,120	121,120
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 31,555	$ 56,614

Note 4 - Intangible Assets an_3

Note 4 - Intangible Assets and Goodwill (Details Textual)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Nov. 24, 2021 USD ($)
Amortization of Intangible Assets	$ 103,366	$ 83,086	$ 206,890	$ 166,133
Impairment of Intangible Assets (Excluding Goodwill), Total			0		$ 2,893,548
Goodwill, Ending Balance	0		0		6,857,790
Goodwill, Impairment Loss	$ 7,231,093	$ 0	$ 7,231,093	$ 0
Measurement Input, Expected Cash Flow Term [Member]
Reporting Unit Measurement Input	10		10
Measurement Input, Long-Term Revenue Growth Rate [Member]
Reporting Unit Measurement Input	4		4
Measurement Input, Discount Rate [Member]
Reporting Unit Measurement Input	65		65
zPREDICTA [Member]
Goodwill, Ending Balance	$ 0		$ 0		6,857,790	$ 7,231,093
Goodwill, Purchase Accounting Adjustments	373,303		373,303
Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination	373,303		373,303
Goodwill, Gross	7,231,093		7,231,093
Goodwill, Impairment Loss	7,231,093		7,231,093
Goodwill, Impaired, Accumulated Impairment Loss	7,231,093		7,231,093
Helomics Holding Corp. [Member]
Goodwill, Ending Balance	0		0		0
Goodwill, Impaired, Accumulated Impairment Loss	$ 23,790,290		$ 23,790,290		$ 23,790,290

Note 4 - Intangible Assets an_4

Note 4 - Intangible Assets and Goodwill - Components of Intangible Assets (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Accumulated Amortization	$ (478,087)	$ (1,102,648)
Net Carrying Amount	3,790,637
Total, Gross Carrying Costs	4,268,724	7,958,314
Total, Net Carrying Amount	3,790,637	3,962,118
Impairment	0	(2,893,548)
Trade Names 1 [Member]
Tradename	80,000	478,000
Tradename	(12,963)	(29,343)
Tradename	67,037	77,917
Impairment, indefinite		370,740
Patents and Trademarks [Member]
Gross Carrying Costs	488,724	453,314
Accumulated Amortization	(241,583)	(230,572)
Net Carrying Amount	247,141	222,742
Impairment, finite		0
Developed Technology Rights [Member]
Gross Carrying Costs	3,500,000	6,382,000
Accumulated Amortization	(211,458)	(432,733)
Net Carrying Amount	3,288,542	3,463,542
Impairment, finite		(2,485,725)
Customer Relationships [Member]
Gross Carrying Costs	200,000	645,000
Accumulated Amortization	(12,083)	(410,000)
Net Carrying Amount	$ 187,917	197,917
Impairment, finite		$ (37,083)

Note 4 - Intangible Assets an_5

Note 4 - Intangible Assets and Goodwill - Estimated Future Amortization Expense (Details)	Jun. 30, 2022 USD ($)
2022	$ 207,068
2023	414,139
2024	414,139
2025	412,056
2026	394,139
Thereafter	1,949,096
Total	$ 3,790,637

Note 4 - Intangible Assets an_6

Note 4 - Intangible Assets and Goodwill - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($)	Nov. 24, 2021	Jun. 30, 2022	Dec. 31, 2021
Goodwill, Ending Balance		$ 0	$ 6,857,790
zPREDICTA [Member]
Cash consideration	$ 10,015,941
Cash	425,727
Accounts receivable	76,549
Prepaid expenses	25,733
Intangible assets	3,780,000
Accrued expenses	(408,825)
Deferred tax liability	(661,658)
Deferred revenue	(452,678)
Goodwill, Ending Balance	$ 7,231,093	$ 0	$ 6,857,790

Note 4 - Intangible Assets an_7

Note 4 - Intangible Assets and Goodwill - Pro Form Information (Details) - zPREDICTA [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue	$ 2,056,484	$ 1,815,560
Net loss attributable to common shareholders	$ (19,251,734)	$ (26,946,564)

Note 4 - Intangible Assets an_8

Note 4 - Intangible Assets and Goodwill - Goodwill (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Goodwill			$ 6,857,790
Impairment	$ (7,231,093)	$ 0	(7,231,093)	$ 0
Goodwill	0		0
zPREDICTA [Member]
Goodwill			6,857,790
Adjustment to fair value	373,303		373,303
Impairment	(7,231,093)		(7,231,093)
Goodwill	$ 0		$ 0

Note 5 - Stockholders' Equity_3

Note 5 - Stockholders' Equity, Stock Options and Warrants (Details Textual) - USD ($)			3 Months Ended			6 Months Ended
	May 16, 2022	Oct. 24, 2019	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	May 15, 2022
Stock Issued During Period, Value, New Issues			$ 6,507,050
Share-Based Payment Arrangement, Expense			39,383		$ 33,243	$ 75,901	$ 598,325
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount			30,234			$ 30,234
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						21 years
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						27 months
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount			$ 72,296			$ 72,296
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Ending Balance (in shares)			366,666			366,666
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				10 years
Maximum [Member] | Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						3 years
Warrants Issued with First May 2022 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,837,280
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.70
Warrants and Rights Outstanding, Term (Year)	5 years 6 months
Existing Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	16,325,433
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.70
Warrants and Rights Outstanding, Term (Year)	5 years 6 months
Existing Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 1
Existing Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 2
Placement Agent Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.75
Sale of Stock, Placement Agent, Warrants Assigned, Number of Securities Called by Warrants, Percent of Shares Sold	7.50%
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percent of Stock Price	125%
May 2022 First Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	3,837,280
Shares Issued, Price Per Share (in dollars per share)	$ 0.60
May 2022 Second Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	8,162,720
Shares Issued, Price Per Share (in dollars per share)	$ 0.60
May 2022 Offerings [Member]
Sale of Stock, Agent Placement Fee, Percent of Gross Proceeds	7.50%
Sale of Stock, Management Fee, Percent of Gross Proceeds	1%
Maximum Expenses Reimbursable to Placement Agent	$ 65,000
Equity Line Purchase Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		104,651				315,000
Issuance or Sale of Equity, Can Be Raised		$ 15,000,000
Stock Issued During Period, Value, New Issues		$ 450,000				$ 236,009
Sale of Stock, Remaining Available Balance			$ 8,877,820			$ 8,877,820

Note 5 - Stockholders' Equity_4

Note 5 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Warrant [Member]
Number of Shares Outstanding (in shares)	31,699,885	7,353,376
Average Exercise Price Outstanding (in dollars per share)	$ 1.66	$ 1.99
Number of Shares Issued (in shares)	21,062,714	29,640,801
Average Exercise Price Issued (in dollars per share)	$ 0.70	$ 1.44
Number of Shares Forfeited (in shares)	(38,640)	0
Average Exercise Price Forfeited (in dollars per share)	$ 0	$ 0
Expired (in shares)	(16,325,433)	(25,233)
Average Exercise Price Expired (in dollars per share)	$ 26.91	$ 10
Number of Shares Exercised (in shares)		(5,269,059)
Average Exercise Price Exercised (in dollars per share)		$ 0.86
Number of Shares Outstanding (in shares)	36,398,526	31,699,885
Average Exercise Price Outstanding (in dollars per share)	$ 0.74	$ 1.66
Share-Based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	1,062,871	1,013,547
Average Exercise Price Outstanding (in dollars per share)	$ 4.83	$ 5.41
Number of Shares Issued (in shares)	14,075	147,230
Average Exercise Price Issued (in dollars per share)	$ 0.51	$ 1.06
Number of Shares Forfeited (in shares)	0	(92,593)
Average Exercise Price Forfeited (in dollars per share)	$ 0	$ 8.64
Expired (in shares)	(41,701)	0
Expired (in dollars per share)	$ 13.41	$ 0
Number of Shares Exercised (in shares)		(5,313)
Average Exercise Price Exercised (in dollars per share)		$ 0.74
Number of Shares Outstanding (in shares)	1,035,245	1,062,871
Average Exercise Price Outstanding (in dollars per share)	$ 4.49	$ 4.83

Note 6 - Derivatives (Details T

Note 6 - Derivatives (Details Textual) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Agent Warrants In Connection With March 2020 Private Placement [Member]
Derivative Liability, Total	$ 9,171		$ 41,336
Derivative, Gain (Loss) on Derivative, Net, Total	32,166	$ (43,249)
Agent Warrants Issued in Connection with May 2020 Offering [Member]
Derivative Liability, Total	10,594		42,646
Derivative, Gain (Loss) on Derivative, Net, Total	32,051	(41,054)
Agent Warrants In Connection With June 2020 Warrant [Member]
Derivative Liability, Total	12,553		$ 45,498
Derivative, Gain (Loss) on Derivative, Net, Total	$ 32,945	$ (45,143)

Note 6 - Derivatives - Change i

Note 6 - Derivatives - Change in Fair Value of Derivative Liabilities (Details) - USD ($)	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Derivative liability balance	$ 127,572	$ 129,480	$ 198,711	$ 294,382
Gain recognized to revalue derivative instrument at fair value	(95,254)	(1,908)	30,909	(95,671)
Derivative liability balance	$ 32,318	$ 127,572	$ 229,620	$ 198,711

Note 7 - Loss Per Share - Share

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Net loss attributable to common shareholders per common shares-basic and diluted		$ (10,391,324)	$ (2,573,932)	$ (13,762,039)	$ (6,462,645)
Weighted average shared used in computation - basic (in shares)	[1]	68,896,506	51,581,762	67,374,250	44,089,157
Effect of diluted stock options, warrants, and preferred stock (2) (in shares)		0	0	0	0
Weighted average common shares outstanding - diluted (in shares)		68,896,506	51,581,762	67,374,250	44,089,157
Loss per common share basic (in dollars per share)		$ (0.15)	$ (0.05)	$ (0.20)	$ (0.15)
Loss per common share diluted (in dollars per share)		$ (0.15)	$ (0.05)	$ (0.20)	$ (0.15)
[1]The following is a summary of the number of underlying shares outstanding at the end of the respective periods that have been excluded from the diluted calculations because the effect on loss per common share would have been anti-dilutive: Six Months ended June 30, 2022 2021 Options 1,035,245 1,013,780 Restricted Stock Units 366,666 325,000 Warrants 36,398,526 31,747,118 Preferred stock: series B 79,246 79,246

Note 7 - Loss Per Share - Antid

Note 7 - Loss Per Share - Antidilutive Securities Excluded from the Diluted Calculations (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities (in shares)	1,035,245	1,013,780
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities (in shares)	366,666	325,000
Warrant [Member]
Antidilutive Securities (in shares)	36,398,526	31,747,118
Series B Convertible Preferred Stock [Member]
Antidilutive Securities (in shares)	79,246	79,246

Note 8 - Segments (Details Text

Note 8 - Segments (Details Textual)	6 Months Ended
	Jun. 30, 2022
Number of Operating Segments	4

Note 8 - Segments - Segments (D

Note 8 - Segments - Segments (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Revenue	$ 371,591		$ 350,207		$ 686,159	$ 630,524
Net loss	(10,391,324)	$ (3,370,715)	(2,573,932)	$ (3,888,713)	(13,762,039)	(6,462,645)
Assets	36,495,767				36,495,767		$ 43,771,271
Corporate, Non-Segment [Member]
Revenue	487		2,000		889	2,000
Net loss	(1,393,045)		(1,144,735)		(2,997,817)	(3,413,685)
Assets	15,122,723				15,122,723		(28,536,489)
Helomics Segment [Member] | Operating Segments [Member]
Revenue	84		7,161		3,722	9,151
Net loss	(946,341)		(1,057,177)		(1,986,069)	(2,284,853)
Assets	1,275,404				1,275,404		1,802,792
Soluble [Member] | Operating Segments [Member]
Revenue	22,225		34,910		35,141	48,985
Net loss	(396,100)		(238,938)		(798,928)	(488,467)
Assets	1,565,394				1,565,394		1,742,445
zPREDICTA [Member] | Operating Segments [Member]
Revenue	71,941		0		90,283
Net loss	(7,554,404)		0		(7,829,190)	0
Assets	3,782,143				3,782,143		10,782,568
Skyline [Member] | Operating Segments [Member]
Revenue	276,854		306,136		556,124	570,388
Net loss	(101,434)		$ (133,082)		(150,035)	$ (275,640)
Assets	$ 14,750,103				$ 14,750,103		$ 906,977